Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):724–729. doi: 10.1038/bjc.1990.367

Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.

S Vitols 1, K Söderberg-Reid 1, M Masquelier 1, B Sjöström 1, C Peterson 1
PMCID: PMC1971505  PMID: 2245164

Abstract

Previous studies have shown that human leukaemic cells and certain tumour tissues have a higher receptor-mediated uptake of low density lipoprotein (LDL) than the corresponding normal cells or tissues. LDL has therefore been proposed as a carrier for anti-cancer agents. In the current study, a water-insoluble mitoclomine derivative (WB 4291) was incorporated into LDL. The WB 4291-LDL complex contained about 1,500 drug molecules per LDL particle and showed receptor-mediated toxicity in vitro as judged from the difference in growth inhibitory effect on normal and mutant (LDL-receptor-negative) cultured Chinese hamster ovary cells. However, cellular drug uptake did not exclusively occur by the receptor pathway since mutant cells were also affected to some extent. The LDL part of the complex had the same plasma clearance and organ distribution as native LDL after i.v. injection in mice and rabbits. Therapeutic effects were observed when Balb-C mice with experimental leukaemia were treated with the complex. After i.p. administration to mice with i.p. leukaemia median survival time was prolonged 2.5-fold and 40% became long time survivors. The effect was weaker (42% increase in life span) after i.v. injections of the complex to mice with i.v. leukaemia.

Full text

PDF
724

Images in this article

726Figure 3
on p.726

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Budd D., Ginsberg H. Hypocholesterolemia and acute myelogenous leukemia. Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer. 1986 Sep 15;58(6):1361–1365. doi: 10.1002/1097-0142(19860915)58:6<1361::aid-cncr2820580630>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  2. Eisenbrand G., Berger M. R., Brix H. P., Fischer J. E., Mühlbauer K., Nowrousian M. R., Przybilski M., Schneider M. R., Stahl W., Tang W. Nitrosoureas. Modes of action and perspectives in the use of hormone receptor affinity carrier molecules. Acta Oncol. 1989;28(2):203–211. doi: 10.3109/02841868909111248. [DOI] [PubMed] [Google Scholar]
  3. Gal D., Ohashi M., MacDonald P. C., Buchsbaum H. J., Simpson E. R. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol. 1981 Apr 15;139(8):877–885. doi: 10.1016/0002-9378(81)90952-2. [DOI] [PubMed] [Google Scholar]
  4. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930. doi: 10.1146/annurev.bi.46.070177.004341. [DOI] [PubMed] [Google Scholar]
  5. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med. 1976 Sep 23;295(13):704–710. doi: 10.1056/NEJM197609232951305. [DOI] [PubMed] [Google Scholar]
  6. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med. 1976 Sep 30;295(14):765–770. doi: 10.1056/NEJM197609302951406. [DOI] [PubMed] [Google Scholar]
  7. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ho Y. K., Smith R. G., Brown M. S., Goldstein J. L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978 Dec;52(6):1099–1114. [PubMed] [Google Scholar]
  9. Hurwitz E., Levy R., Maron R., Wilchek M., Arnon R., Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975 May;35(5):1175–1181. [PubMed] [Google Scholar]
  10. Hynds S. A., Welsh J., Stewart J. M., Jack A., Soukop M., McArdle C. S., Calman K. C., Packard C. J., Shepherd J. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim Biophys Acta. 1984 Oct 4;795(3):589–595. doi: 10.1016/0005-2760(84)90189-9. [DOI] [PubMed] [Google Scholar]
  11. Iwanik M. J., Shaw K. V., Ledwith B. J., Yanovich S., Shaw J. M. Preparation and interaction of a low-density lipoprotein:daunomycin complex with P388 leukemic cells. Cancer Res. 1984 Mar;44(3):1206–1215. [PubMed] [Google Scholar]
  12. Kaneko Y. Thyrotropin-daunomycin conjugate shows receptors-mediated cytotoxicity in cultured thyroid cells. Horm Metab Res. 1981 Feb;13(2):110–114. doi: 10.1055/s-2007-1019187. [DOI] [PubMed] [Google Scholar]
  13. Krieger M., Smith L. C., Anderson R. G., Goldstein J. L., Kao Y. J., Pownall H. J., Gotto A. M., Jr, Brown M. S. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J Supramol Struct. 1979;10(4):467–478. doi: 10.1002/jss.400100409. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Langer T., Strober W., Levy R. I. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest. 1972 Jun;51(6):1528–1536. doi: 10.1172/JCI106949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. 1987 Aug 1;47(15):4105–4108. [PubMed] [Google Scholar]
  17. Masquelier M., Vitols S., Peterson C. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 1986 Aug;46(8):3842–3847. [PubMed] [Google Scholar]
  18. Morgan J., Gray A. G., Huehns E. R. Specific targeting and toxicity of sulphonated aluminium phthalocyanine photosensitised liposomes directed to cells by monoclonal antibody in vitro. Br J Cancer. 1989 Mar;59(3):366–370. doi: 10.1038/bjc.1989.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Norata G., Canti G., Ricci L., Nicolin A., Trezzi E., Catapano A. L. In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. Cancer Lett. 1984 Dec;25(2):203–208. doi: 10.1016/s0304-3835(84)80046-4. [DOI] [PubMed] [Google Scholar]
  20. Rao K. S., Collard M. P., Cornet J., Trouet A. Vinblastine-C4 alkyl maleoyl and amino acid maleoyl derivatives: III. Experimental antitumor activities of lactosaminated serum albumin conjugates. Anticancer Res. 1989 Jul-Aug;9(4):973–979. [PubMed] [Google Scholar]
  21. Trouet A., Deprez-de Campeneere D., De Duve C. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nat New Biol. 1972 Sep 27;239(91):110–112. doi: 10.1038/newbio239110a0. [DOI] [PubMed] [Google Scholar]
  22. Vitols S. G., Masquelier M., Peterson C. O. Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts. J Med Chem. 1985 Apr;28(4):451–454. doi: 10.1021/jm00382a011. [DOI] [PubMed] [Google Scholar]
  23. Vitols S., Gahrton G., Björkholm M., Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet. 1985 Nov 23;2(8465):1150–1154. doi: 10.1016/s0140-6736(85)92679-0. [DOI] [PubMed] [Google Scholar]
  24. Vitols S., Gahrton G., Ost A., Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 1984 May;63(5):1186–1193. [PubMed] [Google Scholar]
  25. Vitols S., Gahrton G., Peterson C. Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells. Cancer Treat Rep. 1984 Mar;68(3):515–520. [PubMed] [Google Scholar]
  26. Weisgraber K. H., Innerarity T. L., Mahley R. W. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem. 1978 Dec 25;253(24):9053–9062. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES